382592-28-1

Basic information

• Product Name: 1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide
• Synonyms: 1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide
• CAS NO: 382592-28-1
• Molecular Formula: C₂₅H₃₈N₆O₅S
• Molecular Weight: 534.67142
• Product Categories: Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 382592-28-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane, Methanol
• CAS DataBase Reference: 1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide(382592-28-1)
• EPA Substance Registry System: 1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide(382592-28-1)

Safety Data

• Hazardous Substances Data: 382592-28-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide is used as an intermediate in the preparation of Udenafil (U250500) for the pharmaceutical industry. Udenafil is a phosphodiesterase 5 inhibitor that is utilized in the treatment of erectile dysfunction, improving blood flow to the penis and facilitating an erection in response to sexual stimulation.
As an intermediate, 1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide plays a crucial role in the synthesis process of Udenafil, contributing to the development of an effective treatment option for patients suffering from erectile dysfunction. Its unique chemical properties and structure enable it to be a valuable component in the creation of this medication, ultimately benefiting the pharmaceutical industry and those who rely on such treatments.

Upstream product

• 51387-90-7 2-(2-AMINOETHYL)-1-METHYLPYRROLIDINE 
• 374776-34-8 4-(5-chlorosulfonyl-2-n-propoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 

Downstream Products

• 268203-93-6 5-[2-propyloxy-5-[2-(1-methyl-2-pyrrolidinyl)ethylaminosulfonyl]phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one 

Relevant articles and documents

PHARMACOLOGICAL COMPOSITION FOR PREVENTION AND TREATMENT OF RESPIRATORY DISEASE CONTAINING PYRAZOLOPYRIMIDINONE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

Disclosed herein is composition for prevention and treatment of respiratory disease containing a pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof as an active ingredient.

HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS

Disclosed herein are substituted phosphodiesterase type 5 enzyme modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

AGENT FOR THE PREVENTION AND TREATMENT OF LIVER DISEASES CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVE

The present invention relates to the pharmaceutical compositionfor prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as an active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cellsand acts directly on the portal vein. Particularly, it may increase the diameter and the amount of blood flow of the portal vein, and finally decrease the pressure thereof. Therefore, pyrazolopyrimidine derivative can be used advantageously for prevention and treatment of hepatic fibrosis, liver cirrhosis caused by hepatic fibrosis, portal hypertension and various complications caused by portal hypertension. In addition, pyrazolopyrimidine derivative according to the present invention can reduce dosing frequency because of its long half-life, and therefore, has an advantage to improve the drug compliance of patients suffering from chronical liver diseases.